# US 2007/0053830 A1 · Particulate materials and compositions for radio therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2007/0053830 A1
- Document ID: US20070053830A1
- Status: Published application
- Kind: A1
- Application number: 10/531,996
- Filed: 2005-03-07
- Published: 2007-03-08
- Earliest claimed: 2004-03-05
- Assignees: XL Sci-Tech, Inc.
- Inventors: Yongren Peng; Xingye Lei
- Web page: https://patentgrep.com/patent/US20070053830A1

## CPC

- A61K 51/1217: {Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols}
- A61N 5/1027: {Interstitial radiation therapy}
- A61K 51/1251: {micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules}
- A61K 51/1255: {Granulates, agglomerates, microspheres}
- A61L 27/425: {of phosphorus containing material, e.g. apatite}
- A61L 27/427: {of other specific inorganic materials not covered by A61L27/422 or A61L27/425}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/58: Materials at least partially resorbable by the body
- A61P 35/00: Antineoplastic agents
- A61L 2300/44: Radioisotopes, radionuclides
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Timed-bioresorbable particulates, particularly microspheres or fibers, may be used as a vehicle for delivery of radioisotopes, such as Y-90 and Pd-103 for localized radiotherapy, or as an embolic device. These particulates may also be embedded in polymers, or dispersed in injectable gels or other injectable media for the treatment of various cancers. The benefit of bioresorption, the ability to control the ratio of radioisotopes in the particulate, especially the gamma and beta ratios such as In-111/Y-90 ratio in a particulate, and the benefit of non-conductive implants are disclosed.

## Claims

### Claim 1

A resorbable implant material for radiotherapy comprising:
(i) a resorbable base glass matrix which is biocompatible;
(ii) a radioactive isotope or combination of radioisotopes, wherein said radioisotope or combination of radioisotopes is incorporated or encapsulated directly and homogeneously into the base glass matrix during the process of manufacturing said base glass matrix, and wherein said base glass matrix does not need or require high energy particle irradiation to convert one or more stable isotopes into radioactive isotopes; and
(iii) an optional nitrogen-rich surface layer formed on the resorbable base glass matrix, the surface layer being of greater durability than the base glass matrix.

### Claim 2 (depends on 1)

The resorbable implant material of claim 1, wherein said resorbable base glass comprises a silicate, borate or phosphate based matrix.

### Claim 3 (depends on 1)

The resorbable implant material of claim 1, wherein said resorbable base glass matrix is a phosphate based matrix.

### Claim 4 (depends on 3)

The resorbable implant material of claim 3, wherein said phosphate based matrix comprises phosphate in combination with calcium, zinc, iron, barium, sodium, strontium, magnesium, aluminum, gallium, indium, lithium, potassium, cesium, rubidium, or combinations thereof.

### Claim 5 (depends on 3)

The resorbable implant of claim 3, wherein said phosphate based glass matrix comprises a calcium to phosphate ratio from about 0.33 to about 1.67.

### Claim 6 (depends on 1)

The resorbable implant material of claim 1, wherein the implant material comprises image enhancing agents suitable for MRI, other imaging agents, diagnostic agents, or combinations thereof.

### Claim 7 (depends on 6)

The resorbable implant material of claim 6, wherein the image enhancing agent is gadolinium, iron or combinations thereof.

### Claim 8 (depends on 3)

The resorbable implant material of claim 3, wherein at least part of said phosphate based matrix contains a borate or silicate.

### Claim 9 (depends on 1)

The resorbable implant material of claim 1, wherein the implant material contains selenium.

### Claim 10 (depends on 1)

The resorbable implant material of claim 1, wherein said optional nitrogen rich surface layer comprises up to about 15 molar % nitrogen.

### Claim 11 (depends on 1)

The resorbable implant material of claim 1, wherein said radioactive isotope or combination of radioisotopes is Y-90, In-111, Pd-103, P-32, Ce-131, Sm-153, Ho-166, Tc-99m, Yb-169, Au-198, Re-188, Re-186, Ir-192, Lu-177, Ba-140, Se-72, I-131, I-125, Sr-90, Dy-165, Er, Tl, Sr, Gd, Y-90/In-111, Y-90/Tc-99m, P-32/In-111, P-32/Tc-99m, Ho-166/In-111, Ho-166/Tc-99m, Sm-153/In-111, Sm-153/Tc-99m, or combinations thereof.

### Claim 12 (depends on 11)

The resorbable implant material of claim 11, wherein said radioactive isotope or combination of radioisotopes is present in said base glass matrix in an amount effective for radiation synovectomy of arthritis.

### Claim 13 (depends on 11)

The resorbabable implant material of claim 11, wherein said radioactive or combination of radioisotopes is present in said base glass matrix in an amount effective for radiation therapy of a tumor.

### Claim 14 (depends on 1)

The resorbable implant material of claim 1, wherein said base glass matrix comprises up to 50 curies of total radioactivity from all isotopes.

### Claim 15 (depends on 1)

The resorbable implant material of claim 1, wherein the resorbable base glass matrix is a particulate, microsphere, porous microsphere, hollow microsphere, microcapsule, fiber, short fiber, small rod, particulate dispersed in biopolymers, particulate dispersed in bioresorbable sutures, particulate dispersed in biocompatible gels a particulate dispersed in other media, or combinations thereof.

### Claim 16 (depends on 1)

The resorbable implant material of claim 1, wherein said implant is a non-conductive implant.

### Claim 17 (depends on 16)

The resorbable implant material of claim 16, wherein said non-conductive implant is radiogaphically detectable.

### Claim 18 (depends on 16)

The resorbable implant material of claim 16, wherein said non-conductive implant is embedded in a non-conductive delivery vehicle.

### Claim 19 (depends on 18)

The resorbable implant material of claim 18, wherein said non-conductive delivery vehicle is a biopolymer, bioresorbable suture, injectable gel, issue adhesive, other media, or combinations thereof.

### Claim 20 (depends on 19)

The resorbable implant material of claim 19, wherein said biopolymer is poly-1-lactic acid in the molecular weight range of 30,000 to 500,000, poly-1-lactic acid co-polymers with polyglycolic acid, polydioanone (PDS II), polyglycaprone 25 (Moncryl), polyglactin 910 (Vicryl), phenyletheretherketone (PEEK), polysulfone (PSU), polyurethane, polypropylene, silicone, polyethylene terephthalate (PET), polyphenylene oxide blends (PPO), polyphenylsulfone (PPSU), polyether sulfone (PES), polyphenylene sulfide (PPS), polyetherimide (PEI), liquid crystal polymer (LCP), or combinations thereof.

### Claim 21

A method of making a resorbable implant material containing a radioactive isotope comprising:
(i) forming a base glass matrix;
(ii) incorporating or encapsulating a radioisotope or combination of radioisotopes directly and homogeneously while forming said glass matrix; and
(ii) optionally nitriding a surface of a biocompatible resorbable base glass matrix.

### Claim 22 (depends on 21)

The method of claim 21, wherein radioisotope or combination of radioisotopes comprises a high energy pure alpha or beta emitter for radiotherapy and a gamma emitter for imaging or diagnostics.

### Claim 23 (depends on 22)

The method of claim 22, wherein the high energy pure beta emitter is Y-90 or P-32 and the gamma emitter is In-111 or Tc-99m.

### Claim 24 (depends on 21)

The method of claim 21, further comprising incorporating image enhancing agents suitable for MRI, other imaging agents, diagnostic agents, or combinations thereof.

### Claim 25 (depends on 21)

The method of claim 21, wherein said radioisotope or combination of radioisotopes are incorporated or encapsulated while forming said base glass matrix without melting bulk glasses.

### Claim 26 (depends on 21)

The method of claim 21, wherein said forming of said base glass matrix comprises:
(a) dissolving all glass components in a solution;
(b) forming spherical dry powders of said solution; and
(c) solidifying said dry spherical powder into solid, porous or hollow microspheres, either in separate processing steps or in a continuous succession.

### Claim 27 (depends on 21)

The method of claim 21, further comprising controlling drying parameters, solidification parameters, and microsphere classification parameters such that resultant porous or hollow microspheres have a density close to that of body fluid to be embolized and a dimension appropriate for embolizing body fluid passage leading to diseased tissues.

### Claim 28 (depends on 27)

The method of claim 27, wherein said body fluid is blood.

### Claim 29 (depends on 27)

The method of claim 27, wherein said density is between about 0.4 and 2.8 grams/mL.

### Claim 30 (depends on 21)

The method of claim 21, comprising embedding said base glass matrix in a delivery vehicle, wherein said vehicle is a biopolymer, bioresorbable suture, injectable gel, issue adhesives, other media, or combinations thereof.

### Claim 31 (depends on 1)

A method of administering radiotherapy to a patient comprising inserting the implant of claim 1 into a patient at a site in need of radiotherapy.

### Claim 32 (depends on 31)

The method of claim 31, wherein the site in need of radiotherapy is a joint, prostate, breast, liver, pancreas or other soft-tissue tumors.

### Claim 33 (depends on 31)

The method of claim 31, wherein said implant material is suspended in a viscous medium.

### Claim 34 (depends on 33)

The method of claim 33, wherein said viscous medium is pyrogen-free 85% glycerol or iodized lipiodol.

### Claim 35 (depends on 31)

The method of claim 31, further comprising real-time monitoring.
